Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Neomorph has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Neomorph's investors include Longwood Fund, Deerfield, Alexandria Venture Investments, Regeneron Ventures, Binney Street Capital.
Neomorph is headquartered in San Diego, United States.
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Neomorph is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neomorph — Funding & Investors." VCBacked, April 13, 2026, https://www.vcbacked.co/company/neomorph. Accessed July 20, 2026.
VCBacked. (2026). Neomorph — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/neomorph
{{cite web |title=Neomorph — Funding & Investors |url=https://www.vcbacked.co/company/neomorph |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated